Observational, multicenter, international study to understand the effect of the COVID-19 pandemic on the treatment of patients with unresectable stage III non-small cell lung carcinoma (NSCLC)
COMMERCIAL POST AUTHORIZATION STUDY
Clinical trial information
- Promoter: ASTRAZENECA UK LTD
- Execution start: 26/01/2022
- End of execution: 30/12/2022
- IP: SILVIA SEQUERO LOPEZ
